Interferons and their potential in the treatment of ocular inflammation

Figures & data

Figure 1 Interferons: immunostimulatory vs immunoregulatory effects.

Table 1 Systemic interferon treatment in ocular inflammatory disease

Author, Year	Type of study	n	Systemic disease (n)	Uveitis (n)	Dose (mio IU)	Interval	Improvement (of uveitis) %
Interferon-α
Deuter 2009^Citation64	Retr. CS	24	None	24	3–6	Daily	62.5–87.5a
Krause 2008^Citation43	Retr. CS	45	BD	45	3–9	3/week	73–92b
Gueudry 2008^Citation47	Retr. CS	32	BD	32	3	3/week	82.1c
Bodaghi 2007^Citation46	Retr. CS	45	BD (23)/other (22)	45	3	3/week	82.6 59
Guillaume-Czitrom 2007^Citation48	Retr. CS	7	Pediatric BD	7	1.5–3	3/week	71.4
Plskova 2007^Citation65	Pros. CS	12	BD (2)/none (10)	12	6	Daily	83 “clinical response”
Tugal-Tutkun 2006^Citation42	Retr. CS	44	BD	44	3–6	Daily	36.4–91d
Kotter 2004^Citation44	Retr. Meta-analysis	338	BD	182	variable	variable	94
Kotter 2004^Citation37	Pros. open label	50	BD	50	6–3	Daily to 3/week	92
Alpsoy 2002^Citation38	Pros., controlled	50	BD	9	6 or placebo	3/week	83 versus 33
Interferon-β
Becker 2005^Citation56	Retr. CS	13	Multiple sclerosis	13	22/44 μg sc (10) 30 mg im (3)	3/week or 1 weekly	71

^a Reduction in cystoid macular edema incl. partial response;

^b 92% any improvement, 78% no recurrence, 73% discontinued pred;

^c 82.1% (no more relapses), 87.5% (+ partial response);

^d 36.4% (no more relapses), 91% (+ partial response)

Abbreviations: mio IU, million international units; sc, subcutaneously; im, intramuscularly; BD, Behçet’s disease; CS, case series.

DeuterCMEfficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitisBr J Ophthalmol200993790691319321469

 PubMed Web of Science ®Google Scholar

KrauseLLong term visual prognosis of patients with ocular Adamantiades-Behcet’s disease treated with interferon-alpha-2aJ Rheumatol200835589690318412306

 PubMed Web of Science ®Google Scholar

GueudryJLong-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet diseaseAm J Ophthalmol2008146683784419027420

 PubMed Web of Science ®Google Scholar

BodaghiBEfficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patientsBr J Ophthalmol200791333533917050581

 PubMed Web of Science ®Google Scholar

Guillaume-CzitromSEfficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s diseaseRheumatology (Oxford)200746101570157317702770

 PubMed Web of Science ®Google Scholar

PlskovaJInterferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitisAm J Ophthalmol20071441556117601428

 PubMed Web of Science ®Google Scholar

Tugal-TutkunIResults of interferon-alfa therapy in patients with Behcet uveitisGraefes Arch Clin Exp Ophthalmol2006244121692169516673135

 PubMed Web of Science ®Google Scholar

KotterIThe use of interferon alpha in Behcet disease: review of the literatureSemin Arthritis Rheum200433532033515079763

 PubMed Web of Science ®Google Scholar

KotterIDifferential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trialSemin Arthritis Rheum200433531131915079762

 PubMed Web of Science ®Google Scholar

AlpsoyEInterferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind studyArch Dermatol2002138446747111939808

 PubMed Web of Science ®Google Scholar

BeckerMDInterferon as a treatment for uveitis associated with multiple sclerosisBr J Ophthalmol200589101254125716170111

 PubMed Web of Science ®Google Scholar